Natraj Proteins Ltd Upgraded to Hold on Technical Improvements and Financial Gains

Quality Assessment: Mixed Fundamentals with Recent Profit Growth

From a quality perspective, Natraj Proteins presents a nuanced picture. The company operates in the refined oil and vanaspati segment, where it has struggled with weak long-term fundamental strength. Over the past five years, net sales have declined at a compound annual growth rate (CAGR) of -7.11%, signalling challenges in expanding its revenue base. Additionally, the average return on equity (ROE) stands at a modest 6.97%, indicating relatively low profitability per unit of shareholders’ funds.

However, the latest quarterly financials for Q4 FY25-26 have shown a marked improvement. The company reported a profit after tax (PAT) of ₹1.11 crore, representing a substantial growth of 244.2% compared to the previous four-quarter average. This surge in profitability has contributed positively to the overall quality rating, suggesting that operational efficiencies or market conditions may be turning in the company’s favour.

Valuation: Attractive Metrics Amid Discounted Pricing

Valuation metrics for Natraj Proteins have become more favourable, supporting the upgrade to Hold. The company’s return on capital employed (ROCE) is currently at 1%, which, while modest, is paired with an enterprise value to capital employed (EV/CE) ratio of 0.7. This low multiple indicates that the stock is trading at a discount relative to its capital base and peers’ historical valuations.

Moreover, the price-to-earnings growth (PEG) ratio stands at an exceptionally low 0.1, reflecting the recent spike in profits relative to the stock price. Despite the stock’s one-year return of -8.33%, the company’s profits have risen by 178.1% over the same period, suggesting that the market may not have fully priced in the improving earnings trajectory. This valuation disconnect provides a compelling reason for investors to reconsider the stock’s potential.

Financial Trend: Positive Quarterly Results Amidst Mixed Long-Term Returns

The financial trend for Natraj Proteins has shown signs of improvement in the short term, driven primarily by the strong Q4 FY25-26 results. The 244.2% growth in quarterly PAT to ₹1.11 crore is a standout figure, signalling a potential turnaround in profitability. This contrasts with the company’s longer-term performance, where it has consistently underperformed the BSE500 and Sensex benchmarks.

Specifically, the stock’s returns over various periods reveal a challenging backdrop: a negative 8.33% return over the past year, and a 22.10% decline over three years, compared to Sensex returns of -6.52% and +16.84% respectively. Over five years, the stock has fallen 26.16%, while the Sensex gained 45.20%. However, the 10-year return of 37.88% still lags the Sensex’s 177.28%, underscoring the company’s struggle to keep pace with broader market gains.

Despite these headwinds, the recent profit growth and valuation discount have contributed to a more positive financial trend outlook, justifying the upgrade to Hold.

Technicals: Shift from Mildly Bearish to Mildly Bullish Momentum

The most significant catalyst for the rating upgrade has been the improvement in technical indicators. The technical grade for Natraj Proteins has shifted from mildly bearish to mildly bullish, reflecting a more favourable market sentiment and momentum.

Key technical signals include a bullish weekly MACD and a mildly bullish monthly MACD, indicating strengthening momentum in both short and medium terms. The weekly Bollinger Bands are bullish, suggesting price volatility is supporting upward movement, while the monthly bands remain sideways, signalling consolidation at higher levels.

Daily moving averages have turned bullish, reinforcing the positive short-term trend. However, some indicators remain mixed: the weekly KST is mildly bearish and the monthly KST bearish, while Dow Theory shows no clear weekly trend and a mildly bearish monthly trend. RSI readings on both weekly and monthly charts show no significant signals, indicating the stock is not overbought or oversold.

On the price front, Natraj Proteins closed at ₹38.95 on 16 July 2026, up 9.94% from the previous close of ₹35.43. The stock’s 52-week range is ₹28.00 to ₹47.90, with the current price closer to the lower end but showing recent strength. This technical improvement has been a decisive factor in the upgrade decision.

Market Capitalisation and Shareholding

Natraj Proteins remains classified as a micro-cap stock, which often entails higher volatility and risk. The majority of its shareholding is held by non-institutional investors, which can contribute to less predictable trading patterns and liquidity constraints. This factor, combined with the company’s sector dynamics, means investors should approach with measured expectations despite the recent upgrade.

Comparative Performance and Outlook

While the stock’s recent returns have outpaced the Sensex over the short term—8.47% versus 0.89% in the past week and 7.30% versus 1.21% in the past month—the longer-term underperformance remains a concern. The company’s ability to sustain profit growth and improve operational metrics will be critical to maintaining the upgraded Hold rating or advancing further.

Investors should also weigh the technical improvements against the mixed fundamental backdrop. The current Mojo Score of 50.0 and Mojo Grade of Hold reflect this balance, indicating neither a strong buy nor a sell stance but rather a cautious optimism.

Conclusion: A Balanced Upgrade Reflecting Technical and Financial Improvements

The upgrade of Natraj Proteins Ltd from Sell to Hold is primarily driven by a shift in technical momentum and encouraging quarterly financial results. The company’s valuation metrics have become more attractive, trading at a discount to peers with a low PEG ratio and reasonable EV/CE multiple. However, long-term fundamental challenges, including weak sales growth and underperformance relative to benchmarks, temper enthusiasm.

For investors, the Hold rating suggests a wait-and-watch approach. The stock shows potential for recovery and value appreciation if the positive trends in profitability and technicals persist. Yet, caution is warranted given the micro-cap status and historical volatility. Monitoring upcoming quarterly results and sector developments will be essential to reassess the stock’s trajectory.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →